Dear Ms. Boisvert:

Please refer to your new drug application (NDA) dated June 27, 2019, received June 27, 2019 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Brukinsa (zanubrutinib) capsules.

This new drug application provides for the use of Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 314.500), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.\(^1\) Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, text for the Patient Package Insert). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.\(^2\)

\(^1\) [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

\(^2\) We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on October 8, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 213217**.” Approval of this submission by FDA is not required before the labeling is used.

**ADVISORY COMMITTEE**

Your application for Brukinsa was not referred to an FDA advisory committee because evaluation of the data when used in the treatment of patients with relapsed or refractory mantle cell lymphoma did not raise significant safety or efficacy issues that were unexpected for a drug of this class.

**ACCELERATED APPROVAL REQUIREMENTS**

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled clinical trials to verify and describe clinical benefit. You are required to conduct such clinical trials with due diligence. If postmarketing clinical trials fail to verify clinical benefit or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530, withdraw this approval. We remind you of your postmarketing requirement specified in your submission dated November 5, 2019. This requirement, along with required completion dates, is listed below.

PMR 3735-1  Complete and submit the final results of Trial BGB-3111-306 - the ongoing randomized, Phase 3 clinical trial of BRUKINSA in combination with rituximab versus bendamustine and rituximab in patients with previously untreated mantle cell lymphoma. The primary endpoint is progression free survival (PFS) as assessed by Independent Review Committee (IRC). Overall survival (OS) is a key secondary endpoint. PFS and OS would be analyzed based on superiority testing. Enrollment of approximately 500 patients is expected.
The timetable you submitted on November 5, 2019 states that you will conduct this trial according to the following schedule:

- **Trial Completion:** 10/2026
- **Final Report Submission:** 02/2027

Submit clinical protocols to your IND 125326 for this product. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each requirement in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial.

Submit final reports to this NDA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated “**Subpart H Postmarketing Requirement(s).**”

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

**POST MARKETING REQUIREMENTS UNDER FDAAA SECTION 505(o)**

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a known serious risk of bleeding, to include fatal and severe bleeding, in patients receiving Bruton's tyrosine kinase (BTK) inhibitors.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.
Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following studies:

PMR 3735-2 Determine the effect of a broad range of concentrations of BRUKINSA on the potential to inhibit platelet function by conducting in vitro studies. Assessment methods should include evaluation of effects of zanubrutinib on platelet aggregation, including GPIb-mediated aggregation. Evaluation should include samples from subjects with and without concomitant conditions associated with platelet dysfunction (e.g., severe renal dysfunction, use of a concomitant anticoagulant, and use of aspirin).

LABORATORY STUDIES: Assess the effect of zanubrutinib on platelet function. Assessment methods should evaluate for effects of zanubrutinib on platelet aggregation, including GPIb mediated aggregation. Evaluation should include patients with concomitant conditions associated with platelet dysfunction (e.g., severe renal dysfunction).

The timetable you submitted on November 5, 2019 states that you will conduct this trial according to the following schedule:

Draft Protocol Submission: 02/2020
Final Protocol Submission: 05/2020
Study Completion: 06/2021
Final Report Submission: 12/2021

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of serious risk of zanubrutinib exposure above those observed at the recommended dose, when administered with concomitant CYP3A4 inhibitors (including ciprofloxacin, diltiazem, erythromycin, fluconazole, posaconazole, voriconazole, and clarithromycin).

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trials:

PMR 3735-3 Conduct an analysis evaluating the pharmacokinetics and safety of zanubrutinib when administered with concomitant CYP3A4 inhibitors (including ciprofloxacin, diltiazem, erythromycin, fluconazole, posaconazole, voriconazole, and clarithromycin) utilizing data from ongoing studies (including but not limited to Studies BGB-3111-AU-003, BGB-3111-214, BGB-3111-215, BGB-3111-302, and BGB-3111-306). Evaluate the effect of each inhibitor on both the C\text{max} and AUC of zanubrutinib and assess the safety (including adverse events, dose modifications, dose interruptions,

The timetable you submitted on November 5, 2019 states that you will conduct this trial according to the following schedule:

- Draft Protocol Submission: 02 / 2020
- Final Protocol Submission: 06 / 2020
- Trial Completion: 12 / 2021
- Final Report Submission: 02 / 2022

Submit clinical protocol(s) to your IND 125326 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitments:
Conduct a clinical pharmacokinetic trial with repeat doses of a moderate CYP3A4 inducer on the single dose pharmacokinetics of zanubrutinib to assess the magnitude of decreased drug exposure and to determine appropriate dosing recommendations. This trial should be designed and conducted in accordance with the FDA Guidance for Industry entitled “Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.”

The timetable you submitted on November 5, 2019 states that you will conduct this trial according to the following schedule:

- Draft Protocol Submission: 04/2020
- Final Protocol Submission: 07/2020
- Study/Trial Completion: 01/2021
- Final Report Submission: 04/2021

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

PROMOTIONAL MATERIALS

Under 21 CFR 314.550, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 314.550, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated
references, and approved Prescribing Information (PI)/Medication Guide/Patient Package Insert (as applicable).

Send each submission directly to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotions (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit promotional materials for accelerated approval products electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.3

REPORTING REQUIREMENTS

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at FDA.gov.4

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas

3 When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

4 http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Rachel McMullen, Senior Regulatory Project Manager, at (240) 402-4574.

Sincerely,

{See appended electronic signature page}

Marc R. Theoret, MD
Deputy Director (Acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information
  - Patient Package Insert or Medication Guide
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use BRUKINSA safely and effectively. See full prescribing information for BRUKINSA.

BRUKINSA™ (zanubrutinib) capsules, for oral use
Initial U.S. Approval: 2019

INDICATIONS AND USAGE
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. (1)

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

DOSAGE AND ADMINISTRATION
• Recommended dose: 160 mg orally twice daily or 320 mg orally once daily; swallow whole with water and with or without food. (2.1)
• Reduce BRUKINSA dose in patients with severe hepatic impairment. (2.2, 8.7)
• Advise patients not to open, break, or chew capsules. (2.1)
• Manage toxicity using treatment interruption, dose reduction, or discontinuation. (2.4)

DOSAGE FORMS AND STRENGTHS
Capsules: 80 mg. (3)

CONTRAINDICATIONS
None. (4)

ADVERSE REACTIONS
The most common adverse reactions (≥ 20%) included neutrophil count decreased, platelet count decreased, upper respiratory tract infection, white blood cell count decreased, hemoglobin decreased, rash, bruising, diarrhea and cough. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact BeiGene at 1-877-828-5596 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
• CYP3A Inhibitors: Modify BRUKINSA dose with moderate or strong CYP3A inhibitors as described. (2.3, 7.1)
• CYP3A Inducers: Avoid co-administration with moderate or strong CYP3A inducers. (7.1)

USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION
Revised: 11/2019
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dose of BRUKINSA is 160 mg taken orally twice daily or 320 mg taken orally once daily until disease progression or unacceptable toxicity.

BRUKINSA can be taken with or without food. Advise patients to swallow capsules whole with water. Advise patients not to open, break, or chew the capsules. If a dose of BRUKINSA is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day.

2.2 Dosage Modification for Use in Hepatic Impairment

The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

2.3 Dosage Modifications for Drug Interactions

Recommended dose modifications of BRUKINSA for drug interactions are provided in Table 1 [see Drug Interactions (7.1)].

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Recommended BRUKINSA Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong CYP3A inhibitor</td>
<td>80 mg once daily</td>
</tr>
<tr>
<td></td>
<td>Interrupt dose as recommended for adverse reactions [see Dosage and Administration (2.4)].</td>
</tr>
<tr>
<td>Moderate CYP3A inhibitor</td>
<td>80 mg twice daily</td>
</tr>
<tr>
<td></td>
<td>Modify dose as recommended for adverse reactions [see Dosage and Administration (2.4)].</td>
</tr>
<tr>
<td>Moderate or strong CYP3A inducer</td>
<td>Avoid concomitant use.</td>
</tr>
</tbody>
</table>

After discontinuation of a CYP3A inhibitor, resume previous dose of BRUKINSA [see Dosage and Administration (2.1, 2.2) and Drug Interactions (7.1)].
2.4 Dosage Modifications for Adverse Reactions

Recommended dose modifications of BRUKINSA for Grade 3 or higher adverse reactions are provided in Table 2:

Table 2: Recommended Dose Modification for Adverse Reaction

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reaction Occurrence</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 or higher non-hematological toxicities</td>
<td>First</td>
<td>Interrupt BRUKINSA Once toxicity has resolved to recovery to Grade 1 or lower or baseline: Resume at 160 mg twice daily or 320 mg once daily</td>
</tr>
<tr>
<td>Grade 3 febrile neutropenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 3 thrombocytopenia with significant bleeding</td>
<td>Second</td>
<td>Interrupt BRUKINSA Once toxicity has resolved to recovery to Grade 1 or lower or baseline: Resume at 80 mg twice daily or 160 mg once daily</td>
</tr>
<tr>
<td>Grade 4 neutropenia (lasting more than 10 consecutive days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 4 thrombocytopenia (lasting more than 10 consecutive days)</td>
<td>Third</td>
<td>Interrupt BRUKINSA Once toxicity has resolved to recovery to Grade 1 or lower or baseline: Resume at 80 mg once daily</td>
</tr>
<tr>
<td></td>
<td>Fourth</td>
<td>Discontinue BRUKINSA</td>
</tr>
</tbody>
</table>

Asymptomatic lymphocytosis should not be regarded as an adverse reaction, and these patients should continue taking BRUKINSA.

3 DOSAGE FORMS AND STRENGTHS

Capsules: Each 80 mg capsule is a size 0, white to off-white opaque capsule marked with “ZANU 80” in black ink.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Hemorrhage

Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax have been reported in 2% of patients treated with BRUKINSA monotherapy. Bleeding events of any grade, including purpura and petechiae, occurred in 50% of patients treated with BRUKINSA monotherapy.
Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

5.2 Infections

Fatal and serious infections (including bacterial, viral, or fungal) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher infections occurred in 23% of patients treated with BRUKINSA monotherapy. The most common Grade 3 or higher infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation have occurred.

Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

5.3 Cytopenias

Grade 3 or 4 cytopenias, including neutropenia (27%), thrombocytopenia (10%), and anemia (8%) based on laboratory measurements, were reported in patients treated with BRUKINSA monotherapy.

Monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.

5.4 Second Primary Malignancies

Second primary malignancies, including non-skin carcinoma, have occurred in 9% of patients treated with BRUKINSA monotherapy. The most frequent second primary malignancy was skin cancer (basal cell carcinoma and squamous cell carcinoma of skin), reported in 6% of patients. Advise patients to use sun protection.

5.5 Cardiac Arrhythmias

Atrial fibrillation and atrial flutter have occurred in 2% of patients treated with BRUKINSA monotherapy. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher events were reported in 0.6% of patients treated with BRUKINSA monotherapy. Monitor signs and symptoms for atrial fibrillation and atrial flutter and manage as appropriate.

5.6 Embryo-Fetal Toxicity

Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than
those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for at least 1 week after the last dose. Advise men to avoid fathering a child during treatment and for at least 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:

- Hemorrhage [see Warnings and Precautions (5.1)]
- Infections [see Warnings and Precautions (5.2)]
- Cytopenias [see Warnings and Precautions (5.3)]
- Second Primary Malignancies [see Warnings and Precautions (5.4)]
- Cardiac Arrhythmias [see Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in the WARNINGS AND PRECAUTIONS reflect exposure to BRUKINSA as a single agent at 160 mg twice daily in 524 patients in clinical trials BGB-3111-AU-003, BGB-3111-206, BGB-3111-205, BGB-3111-210, and BGB-3111-1002 and to BRUKINSA at 320 mg once daily in 105 patients in trials BGB-3111-AU-003 and BGB-3111-1002. Among 629 patients receiving BRUKINSA, 79% were exposed for 6 months or longer and 61% were exposed for greater than one year.

In this pooled safety population, the most common adverse reactions in > 10% of patients who received BRUKINSA were neutrophil count decreased (53%), platelet count decreased (39%), upper respiratory tract infection (38%), white blood cell count decreased (30%), hemoglobin decreased (29%), rash (25%), bruising (23%), diarrhea (20%), cough (20%), musculoskeletal pain (19%), pneumonia (18%), urinary tract infection (13%), hematuria (12%), fatigue (11%), constipation (11%), and hemorrhage (10%).

Mantle Cell Lymphoma (MCL)

The safety of BRUKINSA was evaluated in 118 patients with MCL who received at least one prior therapy in two single-arm clinical trials, BGB-3111-206 [NCT03206970] and BGB-3111-AU-003 [NCT02343120] [see Clinical Studies (14.1)]. The median age of patients who received BRUKINSA in studies BGB-3111-206 and BGB-3111-AU-003 was 62 years (range: 34 to 86), 75% were male, 75% were Asian, 21% were White, and 94% had an ECOG performance status of 0 to 1. Patients had a median of 2 prior lines of therapy (range: 1 to 4). The BGB-3111-206 trial required a platelet count $\geq 75 \times 10^9$/L and an absolute neutrophil count $\geq 1 \times 10^9$/L.
independent of growth factor support, hepatic enzymes ≤ 2.5 x upper limit of normal, total bilirubin ≤ 1.5 x ULN. The BGB-3111-AU-003 trial required a platelet count ≥ 50 x 10⁹/L and an absolute neutrophil count ≥ 1 x 10⁹/L independent of growth factor support, hepatic enzymes ≤ 3 x upper limit of normal, total bilirubin ≤ 1.5 x ULN. Both trials required a CLcr ≥ 30 mL/min. Both trials excluded patients with prior allogeneic hematopoietic stem cell transplant, exposure to a BTK inhibitor, known infection with HIV, and serologic evidence of active hepatitis B or hepatitis C infection and patients requiring strong CYP3A inhibitors or strong CYP3A inducers. Patients received BRUKINSA 160 mg twice daily or 320 mg once daily. Among patients receiving BRUKINSA, 79% were exposed for 6 months or longer and 68% were exposed for greater than one year.

Fatal events within 30 days of the last dose of BRUKINSA occurred in 8 (7%) of 118 patients with MCL. Fatal cases included pneumonia in 2 patients and cerebral hemorrhage in one patient.

Serious adverse reactions were reported in 36 patients (31%). The most frequent serious adverse reactions that occurred were pneumonia (11%), and hemorrhage (5%).

Of the 118 patients with MCL treated with BRUKINSA, 8 (7%) patients discontinued treatment due to adverse reactions in the trials. The most frequent adverse reaction leading to treatment discontinuation was pneumonia (3.4%). One (0.8%) patient experienced an adverse reaction leading to dose reduction (hepatitis B).

Table 3 summarizes the adverse reactions in BGB-3111-206 and BGB-3111-AU-003.

### Table 3: Adverse Reactions (≥ 10%) in Patients Receiving BRUKINSA in BGB-3111-206 and BGB-3111-AU-003 Trials

<table>
<thead>
<tr>
<th>Body System</th>
<th>Adverse Reaction</th>
<th>Percent of Patients (N=118)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>All Grades %</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td>Neutropenia and Neutrophil count decreased</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia and Platelet count decreased</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Leukopenia and White blood count decreased</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Anemia and Hemoglobin decreased</td>
<td>14</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td>Upper respiratory tract infection ¶</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Pneumonia §</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Urinary tract infection</td>
<td>11</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td>Rash ‖</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Bruising *</td>
<td>14</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td>Diarrhea</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>13</td>
</tr>
<tr>
<td>Body System</td>
<td>Adverse Reaction</td>
<td>Percent of Patients (N=118)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>All Grades %</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypertension</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Hemorrhage †</td>
<td>11</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Musculoskeletal pain ‡</td>
<td>14</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Hypokalemia</td>
<td>14</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Cough</td>
<td>12</td>
</tr>
</tbody>
</table>

† Includes fatal adverse reaction
* Bruising includes all related terms containing bruise, bruising, contusion, ecchymosis
† Hemorrhage includes all related terms containing hemorrhage, hematoma
‡ Musculoskeletal pain includes musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis
§ Pneumonia includes pneumonia, pneumonia fungal, pneumonia cryptococcal, pneumonia streptococcal, atypical pneumonia, lung infection, lower respiratory tract infection, lower respiratory tract infection bacterial, lower respiratory tract infection viral
‖ Rash includes all related terms containing rash
¶ Upper respiratory tract infection includes upper respiratory tract infection, upper respiratory tract infection viral

Other clinically significant adverse reactions that occurred in < 10% of patients with mantle cell lymphoma include major hemorrhage (defined as ≥ Grade 3 hemorrhage or CNS hemorrhage of any grade) (5%), hyperuricemia (6%) and headache (4.2%).

Table 4:  Selected Laboratory Abnormalities* (> 20%) in Patients with MCL in Studies BGB-3111-206 and BGB-3111-AU-003

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Percent of Patients (N=118)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
</tr>
<tr>
<td>Neutrophils decreased</td>
<td>45</td>
</tr>
<tr>
<td>Platelets decreased</td>
<td>40</td>
</tr>
<tr>
<td>Hemoglobin decreased</td>
<td>27</td>
</tr>
<tr>
<td>Lymphocytosis †</td>
<td>41</td>
</tr>
<tr>
<td>Chemistry abnormalities</td>
<td></td>
</tr>
<tr>
<td>Blood uric acid increased</td>
<td>29</td>
</tr>
<tr>
<td>ALT increased</td>
<td>28</td>
</tr>
<tr>
<td>Bilirubin increased</td>
<td>24</td>
</tr>
</tbody>
</table>

* Based on laboratory measurements.
† Asymptomatic lymphocytosis is a known effect of BTK inhibition.
7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on BRUKINSA

Table 5: Drug Interactions that Affect Zanubrutinib

<table>
<thead>
<tr>
<th>Moderate and Strong CYP3A Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Impact</strong></td>
</tr>
<tr>
<td>• Co-administration with a moderate or strong CYP3A inhibitor increases zanubrutinib C&lt;sub&gt;max&lt;/sub&gt; and AUC [see Clinical Pharmacology (12.3)] which may increase the risk of BRUKINSA toxicities.</td>
</tr>
<tr>
<td><strong>Prevention or management</strong></td>
</tr>
<tr>
<td>• Reduce BRUKINSA dosage when co-administered with moderate or strong CYP3A inhibitors [see Dosage and Administration (2.3)].</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Moderate and Strong CYP3A Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Impact</strong></td>
</tr>
<tr>
<td>• Co-administration with a moderate or strong CYP3A inducer decreases zanubrutinib C&lt;sub&gt;max&lt;/sub&gt; and AUC [see Clinical Pharmacology (12.3)] which may reduce BRUKINSA efficacy.</td>
</tr>
<tr>
<td><strong>Prevention or management</strong></td>
</tr>
<tr>
<td>• Avoid co-administration of BRUKINSA with moderate or strong CYP3A inducers [see Dosage and Administration (2.3)].</td>
</tr>
</tbody>
</table>

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings in animals, BRUKINSA can cause fetal harm when administered to pregnant women. There are no available data on BRUKINSA use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of zanubrutinib to pregnant rats during the period of organogenesis was associated with fetal heart malformation at approximately 5-fold human exposures (see Data). Women should be advised to avoid pregnancy while taking BRUKINSA. If BRUKINSA is used during pregnancy, or if the patient becomes pregnant while taking BRUKINSA, the patient should be apprised of the potential hazard to the fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data
Embryo-fetal development toxicity studies were conducted in both rats and rabbits. Zanubrutinib was administered orally to pregnant rats during the period of organogenesis at doses of 30, 75, and 150 mg/kg/day. Malformations in the heart (2- or 3-chambered hearts) were noted at all dose levels in the absence of maternal toxicity. The dose of 30 mg/kg/day is approximately 5 times the exposure (AUC) in patients receiving the recommended dose of 160 mg twice daily.

Administration of zanubrutinib to pregnant rabbits during the period of organogenesis at 30, 70, and 150 mg/kg/day resulted in post-implantation loss at the highest dose. The dose of 150 mg/kg is approximately 32 times the exposure (AUC) in patients at the recommended dose and was associated with maternal toxicity.

In a pre- and post-natal developmental toxicity study, zanubrutinib was administered orally to rats at doses of 30, 75, and 150 mg/kg/day from implantation through weaning. The offspring from the middle and high dose groups had decreased body weights preweaning, and all dose groups had adverse ocular findings (e.g. cataract, protruding eye). The dose of 30 mg/kg/day is approximately 5 times the AUC in patients receiving the recommended dose.

### 8.2 Lactation

**Risk Summary**

There are no data on the presence of zanubrutinib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions from BRUKINSA in a breastfed child, advise lactating women not to breastfeed during treatment with BRUKINSA and for at least two weeks following the last dose.

### 8.3 Females and Males of Reproductive Potential

**Pregnancy Testing**

Pregnancy testing is recommended for females of reproductive potential prior to initiating BRUKINSA therapy.

**Contraception**

*Females*

BRUKINSA can cause embryo-fetal harm when administered to pregnant women [see Use in Specific Populations (8.1)]. Advise female patients of reproductive potential to use effective contraception during treatment with BRUKINSA and for at least 1 week following the last dose of BRUKINSA. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.

*Males*

Advise men to avoid fathering a child while receiving BRUKINSA and for at least 1 week following the last dose of BRUKINSA.

### 8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.
8.5 Geriatric Use

Of the 641 patients in clinical studies with BRUKINSA, 49% were ≥ 65 years of age, while 16% were ≥ 75 years of age. No overall differences in safety or effectiveness were observed between younger and older patients.

8.6 Renal Impairment

No dosage modification is recommended in patients with mild to moderate renal impairment (CLcr ≥ 30 mL/min, estimated by Cockcroft-Gault). Monitor for BRUKINSA adverse reactions in patients with severe renal impairment (CLcr < 30 mL/min) or on dialysis [see Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

Dosage modification of BRUKINSA is recommended in patients with severe hepatic impairment [see Dosage and Administration (2.2)]. The safety of BRUKINSA has not been evaluated in patients with severe hepatic impairment. No dosage modification is recommended in patients with mild to moderate hepatic impairment. Monitor for BRUKINSA adverse reactions in patients with hepatic impairment [see Clinical Pharmacology (12.3)].

11 DESCRIPTION

BRUKINSA (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. The empirical formula of zanubrutinib is C_{27}H_{29}N_{5}O_{3} and the chemical name is (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide. Zanubrutinib is a white to off-white powder, with a pH of 7.8 in saturated solution. The aqueous solubility of zanubrutinib is pH dependent, from very slightly soluble to practically insoluble.

The molecular weight of zanubrutinib is 471.55 Daltons.

Zanubrutinib has the following structure:

![Zanubrutinib structure](image)

Each BRUKINSA capsule for oral administration contains 80 mg zanubrutinib and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The capsule shell contains edible black ink, gelatin, and titanium dioxide.
12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Zanubrutinib is a small-molecule inhibitor of BTK. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth.

12.2 Pharmacodynamics

BTK Occupancy in PBMCs and Lymph Nodes
The median steady-state BTK occupancy in peripheral blood mononuclear cells was maintained at 100% over 24 hours at a total daily dose of 320 mg in patients with B-cell malignancies. The median steady-state BTK occupancy in lymph nodes was 94% to 100% following the approved recommended dosage.

Cardiac Electrophysiology
At the approved recommended doses (160 mg twice daily or 320 mg once daily), there were no clinically relevant effects on the QTc interval. The effect of BRUKINSA on the QTc interval above the therapeutic exposure has not been evaluated.

12.3 Pharmacokinetics

Zanubrutinib maximum plasma concentration (Cₘₐₓ) and area under the plasma drug concentration over time curve (AUC) increase proportionally over a dosage range from 40 mg to 320 mg (0.13 to 1 time the recommended total daily dose). Limited systemic accumulation of zanubrutinib was observed following repeated administration.

The geometric mean (%CV) zanubrutinib steady-state daily AUC is 2,295 (37%) ng·h/mL following 160 mg twice daily and 2,180 (41%) ng·h/mL following 320 mg once daily. The geometric mean (%CV) zanubrutinib steady-state Cₘₐₓ is 314 (46%) ng/mL following 160 mg twice daily and 543 (51%) ng/mL following 320 mg once daily.

Absorption
The median tₘₐₓ of zanubrutinib is 2 hours.

Effect of Food
No clinically significant differences in zanubrutinib AUC or Cₘₐₓ were observed following administration of a high-fat meal (approximately 1,000 calories with 50% of total caloric content from fat) in healthy subjects.

Distribution
The geometric mean (%CV) apparent steady-state volume of distribution of zanubrutinib is 881 (95%) L. The plasma protein binding of zanubrutinib is approximately 94% and the blood-to-plasma ratio is 0.7 to 0.8.
Elimination
The mean half-life (t½) of zanubrutinib is approximately 2 to 4 hours following a single oral zanubrutinib dose of 160 mg or 320 mg. The geometric mean (%CV) apparent oral clearance (CL/F) of zanubrutinib is 182 (37%) L/h.

Metabolism
Zanubrutinib is primarily metabolized by cytochrome P450(CYP)3A.

Excretion
Following a single radiolabeled zanubrutinib dose of 320 mg to healthy subjects, approximately 87% of the dose was recovered in feces (38% unchanged) and 8% in urine (less than 1% unchanged).

Specific Populations
No clinically significant differences in the pharmacokinetics of zanubrutinib were observed based on age (19 to 90 years), sex, race (Asian, Caucasian, and Other), body weight (36 to 140 kg), or mild or moderate renal impairment (creatinine clearance [CLcr] ≥ 30 mL/min as estimated by Cockcroft-Gault). The effect of severe renal impairment (CLcr < 30 mL/min) and dialysis on zanubrutinib pharmacokinetics is unknown.

Hepatic Impairment
The total AUC of zanubrutinib increased by 11% in subjects with mild hepatic impairment (Child-Pugh class A), by 21% in subjects with moderate hepatic impairment (Child-Pugh class B), and by 60% in subjects with severe hepatic impairment (Child-Pugh class C) relative to subjects with normal liver function. The unbound AUC of zanubrutinib increased by 23% in subjects with mild hepatic impairment (Child-Pugh class A), by 43% in subjects with moderate hepatic impairment (Child-Pugh class B), and by 194% in subjects with severe hepatic impairment (Child-Pugh class C) relative to subjects with normal liver function.

Drug Interaction Studies
Clinical Studies and Model-Informed Approaches
CYP3A Inhibitors: Co-administration of multiple doses of CYP3A inhibitors increases zanubrutinib Cₘₐₓ and AUC (Table 6).

Table 6: Observed or Predicted Increase in Zanubrutinib Exposure After Co-Administration of CYP3A Inhibitors

<table>
<thead>
<tr>
<th>Co-administered CYP3A Inhibitor</th>
<th>Increase in Zanubrutinib Cₘₐₓ</th>
<th>Increase in Zanubrutinib AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Observed</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole (200 mg once daily)</td>
<td>157%</td>
<td>278%</td>
</tr>
<tr>
<td><strong>Predicted</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clarithromycin (250 mg twice daily) | 175% | 183%
Diltiazem (60 mg three times daily) | 151% | 157%
Erythromycin (500 mg four times daily) | 284% | 317%
Fluconazole (200 mg once daily) | 179% | 177%
Fluconazole (400 mg once daily) | 270% | 284%

**CYP3A Inducers:** Co-administration of multiple doses of rifampin (strong CYP3A inducer) decreased the zanubrutinib C<sub>max</sub> by 92% and AUC by 93%.

Co-administration of multiple doses of efavirenz (moderate CYP3A inducer) is predicted to decrease zanubrutinib C<sub>max</sub> by 58% and AUC by 60%.

**CYP3A Substrates:** Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) C<sub>max</sub> by 30% and AUC by 47%.

**CYP2C19 Substrates:** Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) C<sub>max</sub> by 20% and AUC by 36%.

**Other CYP Substrates:** No clinically significant differences were observed with warfarin (CYP2C9 substrate) pharmacokinetics or predicted with rosiglitazone (CYP2C8 substrate) pharmacokinetics when co-administered with zanubrutinib.

**Transporter Systems:** Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) C<sub>max</sub> by 34% and AUC by 11%. No clinically significant differences in the pharmacokinetics of rosuvastatin (BCRP substrate) were observed when co-administered with zanubrutinib.

**Gastric Acid Reducing Agents:** No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with gastric acid reducing agents (proton pump inhibitors, H2-receptor antagonists).

**In Vitro Studies**

**CYP Enzymes:** Zanubrutinib is an inducer of CYP2B6.

**Transporter Systems:** Zanubrutinib is likely to be a substrate of P-gp. Zanubrutinib is not a substrate or inhibitor of OAT1, OAT3, OCT2, OATP1B1, or OATP1B3.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies have not been conducted with zanubrutinib.

Zanubrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an *in vivo* bone marrow micronucleus assay in rats.
A combined male and female fertility and early embryonic development study was conducted in rats at oral zanubrutinib doses of 30 to 300 mg/kg/day. Male rats were dosed 4 weeks prior to mating and through mating and female rats were dosed 2 weeks prior to mating and to gestation day 7. No effect on male or female fertility was noted but at the highest dose tested, morphological abnormalities in sperm and increased post-implantation loss were noted. The high dose of 300 mg/kg/day is approximately 10 times the human recommended dose, based on body surface area.

**14 CLINICAL STUDIES**

**14.1 Mantle Cell Lymphoma**

The efficacy of BRUKINSA was assessed in BGB-3111-206 [NCT03206970], a Phase 2, open-label, multicenter, single-arm trial of 86 previously treated patients with MCL who had received at least one prior therapy. BRUKINSA was given orally at a dose of 160 mg twice daily until disease progression or unacceptable toxicity.

The median age of patients was 60.5 years (range: 34 to 75) and the majority were male (78%). The median time since diagnosis to study entry was 30 months (range: 3 to 102) and the median number of prior therapies was 2 (range: 1 to 4). The most common prior regimens were CHOP-based (91%) followed by rituximab-based (74%). The majority of patients had extranodal involvement (71%) and refractory disease (52%). Blastoid variant of MCL was present in 14% of patients. The MIPI score was low in 58%, intermediate in 29%, and high risk in 13%.

The efficacy of BRUKINSA was also assessed in BGB-3111-AU-003 [NCT02343120], a Phase 1/2, open-label, dose-escalation, global, multicenter, single-arm trial of B-cell malignancies including 32 previously treated MCL patients treated with BRUKINSA. BRUKINSA was given orally at doses of 160 mg twice daily or 320 mg daily. The median age of patients with previously treated MCL was 70 years (range: 42 to 86), and 38% of patients were ≥ 75 years old. Most patients were male (69%) and Caucasian (78%). The MIPI score was low in 28%, intermediate in 41%, and high risk in 31%.

Tumor response was according to the 2014 Lugano Classification for both studies, and the primary efficacy endpoint was overall response rate as assessed by an Independent Review Committee.

**Table 7: Efficacy Results in Patients with MCL by Independent Review Committee**

<table>
<thead>
<tr>
<th></th>
<th>Study BGB-3111-206 (N=86)</th>
<th>Study BGB-3111-AU-003 (N=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORR (95% CI)</strong></td>
<td>84% (74, 91)</td>
<td>84% (67, 95)</td>
</tr>
<tr>
<td><strong>CR</strong></td>
<td>59%</td>
<td>22%*</td>
</tr>
<tr>
<td><strong>PR</strong></td>
<td>24%</td>
<td>62%</td>
</tr>
<tr>
<td><strong>Median DoR in months (95% CI)</strong></td>
<td>19.5 (16.6, NE)</td>
<td>18.5 (12.6, NE)</td>
</tr>
</tbody>
</table>

Reference ID: 4520008
16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

<table>
<thead>
<tr>
<th>Package Size</th>
<th>Content</th>
<th>NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>120-count</td>
<td>Bottle with a child-resistant cap containing 120 capsules</td>
<td>72579-011-02</td>
</tr>
<tr>
<td></td>
<td>80 mg, white to off-white opaque capsule, marked with “ZANU 80” in black ink</td>
<td></td>
</tr>
</tbody>
</table>

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise patients to read the FDA-approved patient labeling (Patient Information).

Hemorrhage

Inform patients to report signs or symptoms of severe bleeding. Inform patients that BRUKINSA may need to be interrupted for major surgeries or procedures [see Warnings and Precautions (5.1)].

Infections

Inform patients to report signs or symptoms suggestive of infection [see Warnings and Precautions (5.2)].

Cytopenias

Inform patients that they will need periodic blood tests to check blood counts during treatment with BRUKINSA [see Warnings and Precautions (5.3)].

Second Primary Malignancies

Inform patients that other malignancies have been reported in patients who have been treated with BRUKINSA, including skin cancer. Advise patients to use sun protection [see Warnings and Precautions (5.4)].

Cardiac Arrhythmias

Counsel patients to report any signs of palpitations, lightheadedness, dizziness, fainting, shortness of breath, and chest discomfort [see Warnings and Precautions (5.5)].

Embryo-Fetal Toxicity
Advise women of the potential hazard to a fetus and to avoid becoming pregnant during treatment and for at least 1 week after the last dose of BRUKINSA [see Warnings and Precautions (5.6)].

Advise males with female sexual partners of reproductive potential to use effective contraception during BRUKINSA treatment and for at least 1 week after the last dose of BRUKINSA [see Use in Specific Populations (8.3)].

Lactation

Advise females not to breastfeed during treatment with BRUKINSA and for at least 2 weeks after the last dose [see Use in Specific Populations (8.2)].

Administration Instructions

BRUKINSA may be taken with or without food. Advise patients that BRUKINSA capsules should be swallowed whole with a glass of water, without being opened, broken, or chewed [see Dosage and Administration (2.1)].

Missed Dose

Advise patients that if they miss a dose of BRUKINSA, they may still take it as soon as possible on the same day with a return to the normal schedule the following day [see Dosage and Administration (2.1)].

Drug Interactions

Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications, vitamins, and herbal products [see Drug Interactions (7)].

Distributed and Marketed by:
BeiGene USA, Inc.
San Mateo, CA 94403
BRUKINSA™ is a trademark owned by BeiGene, Ltd.
© BeiGene, Ltd. 2019
What is BRUKINSA?
BRUKINSA is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
It is not known if BRUKINSA is safe and effective in children.

Before taking BRUKINSA, tell your healthcare provider about all of your medical conditions, including if you:
- have bleeding problems.
- have had recent surgery or plan to have surgery. Your healthcare provider may stop BRUKINSA for any planned medical, surgical, or dental procedure.
- have an infection.
- have or had heart rhythm problems.
- have high blood pressure.
- have liver problems, including a history of hepatitis B virus (HBV) infection.
- are pregnant or plan to become pregnant. BRUKINSA can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with BRUKINSA.
  - **Females** should not become pregnant during treatment and for at least 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for at least 1 week after the last dose of BRUKINSA.
  - **Males** should avoid getting female partners pregnant during treatment and for at least 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for at least 1 week after the last dose of BRUKINSA.
- are breastfeeding or plan to breastfeed. It is not known if BRUKINSA passes into your breast milk. Do not breastfeed during treatment with BRUKINSA and for at least 2 weeks after your last dose of BRUKINSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.

How should I take BRUKINSA?
- Take BRUKINSA exactly as your healthcare provider tells you to take it.
- Do not change your dose or stop taking BRUKINSA unless your healthcare provider tells you to.
- Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking BRUKINSA if you develop certain side effects.
- Take BRUKINSA with or without food.
- Swallow BRUKINSA capsules whole with a glass of water. Do not open, break, or chew the capsules.
- If you miss a dose of BRUKINSA, take it as soon as you remember on the same day. Return to your normal schedule the next day.

What are the possible side effects of BRUKINSA?
BRUKINSA may cause serious side effects, including:

- **Bleeding problems** (hemorrhage) that can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:
  - blood in your stools or black stools (looks like tar)
  - pink or brown urine
  - unexpected bleeding, or bleeding that is severe or you cannot control
  - vomit blood or vomit that looks like coffee grounds
  - cough up blood or blood clots
  - increased bruising
  - dizziness
  - weakness
  - confusion
  - changes in speech
  - headache that lasts a long time

- **Infections** that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.

- **Decrease in blood cell counts**. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with BRUKINSA, but can also be severe. Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
- **Second primary cancers.** New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin. Use sun protection when you are outside in sunlight.
- **Heart rhythm problems (atrial fibrillation and atrial flutter).** Tell your healthcare provider if you have any of the following signs or symptoms:
  - your heartbeat is fast or irregular
  - feel lightheaded or dizzy
  - pass out (faint)
  - shortness of breath
  - chest discomfort

### The most common side effects of BRUKINSA include:
- decreased white blood cells
- decreased platelet count
- rash
- diarrhea
- upper respiratory infection
- decreased red blood cells (anemia)
- bruising
- cough

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### How should I store BRUKINSA?
- Store BRUKINSA capsules at room temperature between 68°F to 77°F (20°C to 25°C).
- BRUKINSA comes in a bottle with a child-resistant cap.

**Keep BRUKINSA and all medicines out of the reach of children.**

### General information about the safe and effective use of BRUKINSA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use BRUKINSA for a condition for which it was not prescribed. Do not give BRUKINSA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about BRUKINSA that is written for healthcare professionals.

### What are the ingredients in BRUKINSA?
- **Active ingredient:** zanubrutinib
- **Inactive ingredients:** colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.
  Capsule shell contains edible black ink, gelatin, and titanium dioxide.
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARC R THEORET
11/14/2019 02:30:45 PM